Skip to main content
Clinical Trials/EUCTR2006-003170-99-IT
EUCTR2006-003170-99-IT
Active, not recruiting
Not Applicable

Evaluation of efficacy and safety of Intravitreal bevacizumab versus intravitreal bevacizumab combined with juxtascleral anecortave acetate for the treatment exudative age-related macular degeneration - IVB JSA

IVERSITA DEGLI STUDI DI UDINE0 sitesMarch 15, 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
IVERSITA DEGLI STUDI DI UDINE
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 15, 2007
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
IVERSITA DEGLI STUDI DI UDINE

Eligibility Criteria

Inclusion Criteria

  • Patients who are 50 year old or older. Patients willing to sign a written informed consent. Patients with age\-related macular degeneration and subfoveal choroidal neovascularization, primary when the lesion characteristics controindicate standard treatments, i.e. large occult neovascularization, greater than 4 disc areas or recurrent after standard treatment increase of lesione size by 10 and/or visual loss equal or greater than 2 ETDRS lines after photodynamic therapy with verteporfin
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Concomitant ocular disease in the study eye that could affect visual acuity Prior treatment of the study eye with photodinamic therapy, laser photocoagulation within 90 days preceeding day 1 or any other experimental treatmentPrior ocular surgery within 60 days preceeding baseline Uncontrolled blood pressure Previous stroke or myocardial infarction

Outcomes

Primary Outcomes

Not specified

Similar Trials